Imunon (NASDAQ:IMNN) Earns Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report released on Wednesday,Benzinga reports. D. Boral Capital currently has a $29.00 price target on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 price objective on shares of Imunon in a research note on Wednesday, March 26th.

Imunon Stock Performance

IMNN stock opened at $0.81 on Wednesday. The firm has a market cap of $11.91 million, a P/E ratio of -0.43 and a beta of 1.75. Imunon has a 1 year low of $0.64 and a 1 year high of $3.65. The stock has a 50-day simple moving average of $0.90 and a 200-day simple moving average of $0.88.

Institutional Trading of Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC raised its holdings in shares of Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the quarter. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 at the end of the most recent quarter. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.